Investment Stage – Series A
Storm Therapeutics is currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases.
Storm Therapeutics Website
Spex Capital Ltd is an appointed representative of J8 Capital Management LLP which is authorised and regulated by the Financial Conduct Authority.
©2022 · Spex Capital
©2021 · Spex Capital